Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Dr A Patel, University of Sydney, Sydney, New South Wales, Australia; email@example.com
In type 2 diabetes, does intensive glucose control prevent adverse outcomes more than standard glucose control?
randomised controlled trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]).
blinded (outcome adjudication committee).
median 5 years.
215 centres in 20 countries worldwide.
11 140 patients ⩾55 years of age (mean age 66 y, 58% men) who had type 2 diabetes and a history of, or risk factors for, vascular disease. Patients requiring insulin were excluded.
intensive glucose control with gliclazide, modified-release, 30–120 mg/day, and other non-sulfonylurea drugs as needed to achieve a target glycated haemoglobin (HbA1c) concentration ⩽6.5% (n = 5571) or standard glucose control with drugs other than gliclazide (n = 5569).
composite of major macrovascular events (non-fatal myocardial infarction or stroke, or death from cardiovascular causes) and composite of major microvascular events (new or worsening nephropathy or retinopathy). Secondary outcomes included new-onset microalbuminuria and severe hypoglycaemia.
95% (intention-to-treat analysis).
Source of funding: Servier and National Health and Medical Research Council of Australia.